Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

926TiP - Phase II trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M SCCHN)

Date

16 Sep 2021

Session

ePoster Display

Topics

Immunotherapy

Tumour Site

Head and Neck Cancers

Presenters

Grzegorz Obara

Citation

Annals of Oncology (2021) 32 (suppl_5): S786-S817. 10.1016/annonc/annonc704

Authors

G. Obara1, J. Sun2, D. Loo3, C. Bohac4

Author affiliations

  • 1 Medical Oncology, Comprehensive Cancer Centers of Nevada, 89169 - Las Vegas/US
  • 2 Biostatistics, MacroGenics, Inc., Rockville/US
  • 3 Research, MacroGenics, Inc., 94005 - Brisbane/US
  • 4 Clinical Development, MacroGenics, Inc., 20850 - Rockville/US
More

Abstract 926TiP

Background

Head and neck cancer accounts for >650,000 new cases and nearly 330,000 annual deaths worldwide as of 2018. Patients with R/M SCCHN have a poor prognosis with median overall survival <1 year. PD-1 and PD-L1 blockade has shown antitumor activity in advanced SCCHN. Enoblituzumab is an investigational Fc-modified monoclonal antibody that binds B7-H3. B7-H3 is overexpressed in many cancers including SCCHN, but not in most normal tissues. Retifanlimab (INCMGA00012) is an investigational anti-PD-1 monoclonal antibody. Tebotelimab is an investigational, Fc-bearing bispecific, tetravalent DART® molecule designed to bind PD-1 and LAG-3 and sustain/restore function of T cells. Tebotelimab has demonstrated improved T-cell responses in vitro beyond that observed with anti-PD-1 and anti-LAG-3 antibodies alone or in combination. In a phase I study of enoblituzumab plus pembrolizumab, study drug was well tolerated. The overall response rate of PD-1/PD-L1 inhibitor-naïve SCCHN patients (post platinum) was 33% (6/18), including 1 confirmed complete and 5 confirmed partial responses, providing a rationale for further development of this combination in R/M SCCHN.

Trial design

This is an open-label, non-randomized study in first-line treatment of patients with R/M SCCHN, with first patient enrolled in March 2021. Approximately 50 patients CPS >=1 will receive enoblituzumab 15 mg/kg plus 375 mg retifanlimab and 30 patients CPS<1 will receive enoblituzumab 15mg/kg plus 600 mg tebotelimab. Dosing is Q3W with tumor assessment at end of Cycle 2 and every 3 cycles thereafter. In the tebotelimab cohort, safety data will be reviewed for dose limiting toxicities through Cycle 2 Day 7 on the 1st 12 pts. All patients will be followed for survival after receipt of the last dose of study drug.

Clinical trial identification

NCT04634825.

Editorial acknowledgement

Legal entity responsible for the study

MacroGenics, Inc.

Funding

MacroGenics, Inc.

Disclosure

J. Sun: Financial Interests, Personal, Full or part-time Employment: MacroGenics, Inc. D. Loo: Financial Interests, Personal, Full or part-time Employment: MacroGenics, Inc.; Financial Interests, Personal, Stocks/Shares: MacroGenics, Inc. C. Bohac: Financial Interests, Personal, Full or part-time Employment: MacroGenics, Inc.; Financial Interests, Personal, Stocks/Shares: MacroGenics, Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.